Letter: Cheaper drugs that work
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.MAJOR pharmaceutical producers are wrong to say that the parallel drugs importing can be "harmful to patients" ("Cut- price drugs firms make pounds 150m from NHS", 31 May). I can refute this because my job is to check that one of these firms meets the safety standards of the Medicines Control Agency (MCA).
First, the storage conditions ensure that there is no product deterioration. In fact, most drugs are stored for longer periods in other parts of the supply chain. Secondly, packing and repacking systems have built-in check routines to prevent contamination by extraneous materials.
In addition, product recall systems, should they be necessary, are in place and approved by the MCA. And no pack goes out with a foreign-language patient instruction leaflet. These are removed and replaced by a leaflet in English, which is approved by the MCA. All parallel imported products have to be licensed before sale.
John R Baker
Great Barton, Suffolk
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments